TrialCancer2024

NRG-GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer.

Bobbie J Rimel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.